Beneficial effect of CV-4151 (isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model
- 1 July 1995
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 79 (1) , 95-107
- https://doi.org/10.1016/0049-3848(95)00094-8
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim resultsBMJ, 1988
- Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.Circulation, 1986
- Cv-4151 — a potent, selective thromboxane A2synthetase inhibitorThrombosis Research, 1986
- Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of .omega.-pyridylalkenoic acidsJournal of Medicinal Chemistry, 1985
- Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis.Circulation, 1985
- Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells.Journal of Clinical Investigation, 1984
- Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.Journal of Clinical Investigation, 1983
- PHARMACOLOGICAL INTERACTIONS BETWEEN PROSTACYCLIN AND THROMBOXANESBritish Medical Bulletin, 1983
- Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatromBiochemical Pharmacology, 1983
- Synthesis of Prostacyclin from Platelet-derived Endoperoxides by Cultured Human Endothelial CellsJournal of Clinical Investigation, 1980